Julie Gralow/citycancerchallenge.org
Nov 21, 2024, 06:27
Julie Gralow: Comprehensive Genomic Profiling Improves Precision Therapy Use And Patient Survival
Julie Gralow, Chief Medical Officer of ASCO, shared a post on LinkedIn:
“Comprehensive Genomic Profiling Improves Precision Therapy Use And Patient Survival.
- 2/3rds of patients with advanced cancer found to be candidates for precision therapies
- Among patients with sufficient follow-up, those who received targeted therapies had median OS of 25 months vs 17 months with chemo alone.”
More posts featuring Julie Gralow.
Julie Gralow is the Chief Medical Officer (CMO) of the American Society of Clinical Oncology (ASCO). Previously, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington School of Medicine, Professor in the Clinical Research Division of the Fred Hutchinson Cancer Research
Center, as well as Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. She is the founder of the Women’s Empowerment Cancer Advocacy Network (WE CAN).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12